| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 9
| Issue : 4 | Page : 365-369 |
|
|
Effect of ondansetron on prevention of post-induction hypotension in elderly patients undergoing general anesthesia: A randomized, double-blind placebo-controlled clinical trial
Mohammad Golparvar1, Mahmoud Saghaei1, Mohammad Ali Saadati1, Shadi Farsaei2
1 Department of Anesthesia, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran
Correspondence Address:
Mahmoud Saghaei
Department of Anesthesia, Isfahan University of Medical Sciences, Isfahan
Iran
 Source of Support: Funded by the Research Department, Isfahan University of Medical Sciences, Isfahan, Iran. Proposal No: 393598,, Conflict of Interest: None  | Check |
DOI: 10.4103/1658-354X.159455
Clinical trial registration UMIN000013466
|
|
|
Background: Elderly patients are susceptible to post-induction hypotension. Volume loading and vasopressors for prevention of hypotension in elderly patients may increase perioperative cardiovascular risks. Ondansetron by blocking Bezold-Jarisch reflex (BJR) through inhibition of serotonin receptors has been effective in the prevention of post-spinal hypotension, and bradycardia. Bradycardia frequently accompanies post-induction hypotension in elderly patients, which signifies a possible preventing role for ondansetron. No previous study has evaluated the prophylactic effects of ondansetron for the prevention of post-induction hypotension. Materials and Methods: In this randomized placebo-controlled clinical trial, ondansetron 4 mg was given intravenously to 65 elderly patients, 20 min before induction of general anesthesia, and the rate of post-induction hypotension defined as 25% or more reduction in mean arterial blood pressure, compared with a placebo groups. Results: A total of 114 patients completed the study (58 in ondansetron and 56 in the placebo group). Proportions of post-induction hypotension were 9 (16%) and 25 (45%) in ondansetron and placebo groups, respectively, (P = 0.001). Forty-five patients (40%) developed bradycardia. Rates of bradycardia were not significantly different between two groups. Conclusions: The results of this study show the effectiveness of intravenous ondansetron for prevention of post-induction hypotension in elderly patients. The mechanism of this effect largely is unknown. Role of ondansetron for prevention of post-induction hypotension may not fully understandable by its interaction with BJR, as has been shown in post-spinal hypotension. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
